Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States f...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hemasphere
Glavni autori: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Tang, Derek, Abraham, Pranav, Lord-Bessen, Jennifer, Rose, Shelonitda, Guo, Shien, Liao, Weiqin, Mesa, Ruben A.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8096470/
https://ncbi.nlm.nih.gov/pubmed/33969275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000562
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items